Home
Applications
- Indications
Business
Technology
Investors
News
About Us
Contact Us

Chromosome conformation signatures as a clinical tool for diagnosis, prognosis and disease understanding in ALS

June 22, 2018

|In Episwitch Publication

|By Aroul Ramadass

ENCALS (2018) 20-22 June, Oxford, UK.

Recent Posts

Development and validation of baseline predictive biomarkers for response to immuno-checkpoint treatments in the context of multiline and multitherapy cohorts using EpiSwitch™ epigenetic profiling
Development and validation of baseline predictive biomarkers for response to avelumab in second-line (2L) non-small cell lung cancer(NSCLC) using EpiSwitch™ epigenetic profiling
Oxford BioDynamics’ EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs
OBD to appoint Professor Iain McInnes to its Scientific Advisory Board
Oxford BioDynamics notes first patient enrolled in ALS biomarker study sponsored by Mitsubishi Tanabe Pharma America

Archives

Categories

Episwitch Publication
Events
Milestones
People
Publications
Uncategorized

Meta

Log in
Entries RSS
Comments RSS
WordPress.org

Prev
Next

Terms of Use
Site Map

Privacy Policy
Cookies Policy

Regulated and Licensed by Human Tissue Authority
License No. 12571

© 2002-2018 Oxford Biodynamics Plc

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with this.Ok Read more